Navigation Links
Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer
Date:2/27/2009

ffer recurrent, advanced disease after definitive local therapy with radiation or prostatectomy and systemic treatment. One process by which prostate cancers may develop resistance to systemic treatment is by increasing the expression of proteins that inhibit apoptosis (programmed cell death). The most recognized group of such proteins are the antiapoptotic members of the Bcl-2 family, including Bcl-2, Bcl-XL, and Mcl-1. Overexpression of Bcl-2 family proteins in human tumor specimens has been reported by several groups to be associated with recurrence, more advanced stage, treatment resistance, the development of hormone-resistance, and shortened survival in prostate cancer.

About AT-101

AT-101 is an orally-active, pan-Bcl-2 inhibitor (including Bcl-2, Bcl-xL, Bcl-w, and Mcl-1 inhibition), that has been shown to directly induce apoptosis by operating as a BH3 mimetic and indirectly as an independent upregulator of Noxa and Puma. By blocking the binding of Bcl-2 family members with proapoptotic proteins and upregulating specific proapoptotic factors, AT-101 lowers the threshold for cancer cells to undergo apoptosis in various tumor types. In Phase I and Phase II trials, AT-101 has demonstrated single-agent cytoreductive activity in chronic lymphocytic leukemia (CLL), non-Hodgkins lymphoma (NHL), and prostate cancer. Phase II combination trials are ongoing in hormone-refractory prostate cancer and non-small cell lung cancer (with Taxotere(R) [docetaxel]), B-cell malignancies (with Rituxan(R) [rituximab]), small cell lung cancer (with Hycamtin(R) [topotecan]), glioma (with Temodar(R) [temozolomide], +/- chemoradiotherapy [XRT]) and in esophageal cancer (with docetaxel, 5-fluorouracil and XRT). Recently, two double-blinded, randomized, controlled trials of the docetaxel + AT-101 combination were opened in hormone-refractory prostate cancer and non-small cell lung cancer, both indications in which docetaxel is approved as a single age
'/>"/>

SOURCE Ascenta Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
2. ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimers Disease
3. BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine
4. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
5. Cerenis Therapeutics In-Licenses Intellectual Property for New Treatment of Aortic Valve Stenosis
6. PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy
7. DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
8. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
9. Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
10. Phico Therapeutics Receives GBP1 Million Award From the Wellcome Trust to Take Anti-MRSA Nasal Product Through Early Clinical Trials
11. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014 Arbor Pharmaceuticals, LLC. ... Global Markets Direct,s, ,Arbor Pharmaceuticals, LLC. - ... of the Arbor Pharmaceuticals, LLC.,s pharmaceutical research and ... on the current therapeutic developmental pipeline of Arbor ... stages, therapeutics assessment by drug target, mechanism of ...
(Date:9/30/2014)... DENVER , Sept. 30, 2014  According ... "the world of cancer clinical trials is going ... clinical trials and the work of the current ... these types of ,next generation, clinical trials, which ... tomorrow."  The company has been ...
(Date:9/30/2014)... , Sept. 30, 2014 A study ... (OCT), offered a new look at the composition of ... how physicians understand and treat the disease, a leading ... at Baptist Health Lexington between September 2010 and May ... the Journal of the American College of Cardiology ...
Breaking Medicine Technology:Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Small Denver Company Pharmatech driving a large revolution in how cancer clinical trials are managed 2New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2
... Combination with CRESTOR (rosuvastatin calcium) Demonstrates Similar Lipid Effects ... ... Population, SAN FRANCISCO, June 7 ... type 2 diabetes,that were enrolled in a Phase III study showed ...
... the ADA,s Annual Scientific Sessions, SAN FRANCISCO, ... of the dose-finding study for its new,injectable diabetes ... American Diabetes Association,s (ADA) 68th Annual Scientific Sessions,meeting ... that AVE0010 was well tolerated and significantly,improved glycemic ...
Cached Medicine Technology:Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes 2Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes 3Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes 4New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 2New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 3New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 4
(Date:10/1/2014)... Wi (PRWEB) October 01, 2014 UP4 ... of UP4 WOMEN’S probiotic to The National Network to ... of October. This organization was chosen through nationwide polling ... website and social media outlets. , “We are ... receive a portion of every sale of UP4 Women’s ...
(Date:10/1/2014)... This weekend Pope Francis drew world-wide attention to the problem ... seniors in St. Peter's Square in the Vatican, he decried ... the elderly is as inhuman as that against children," Pope ... discarded, victims of an abandonment that is tantamount to hidden ... is hurting our world so much," he said. , His ...
(Date:10/1/2014)... Los Angeles, CA (PRWEB) October 01, 2014 ... buyer power score of 3.1 out of 5, ... freezer users include food and beverage manufacturers, food ... manufacturers. As a result of these users' diversity, ... growth. As such, rising industrial production, consumer spending ...
(Date:10/1/2014)... 01, 2014 Nearly a year-and-a-half after ... County District Court jury awarded him $4.75 million; Michael ... years old. Casper had been too sick to ... According to the Court Documents (District Court, Pueblo County ... a benign non-cancerous condition of his prostate, when he ...
(Date:9/30/2014)... (HealthDay News) -- There,s no genetic evidence that high ... a new study says. Some previous research had ... people against type 2 diabetes, raising the possibility of ... sugar disease. In this study, British researchers investigated ... focusing on genes that control blood levels of vitamin ...
Breaking Medicine News(10 mins):Health News:UP4 Probiotics Partners with The National Network to End Domestic Violence 2Health News:Pope Francis Shines New Spotlight on Neglect of Elderly, Survey Finds Elder Self-Neglect is a Growing and Hidden Problem in U.S. says NAPGCM 2Health News:Pope Francis Shines New Spotlight on Neglect of Elderly, Survey Finds Elder Self-Neglect is a Growing and Hidden Problem in U.S. says NAPGCM 3Health News:Industrial Freezers Procurement Category Market Research Report Now Available from IBISWorld 2Health News:Industrial Freezers Procurement Category Market Research Report Now Available from IBISWorld 3Health News:Industrial Freezers Procurement Category Market Research Report Now Available from IBISWorld 4Health News:Law Offices of D.R. Jones Client Wins 4.7 Million Dollar Verdict, Insurance Company Files Motion for a New Trial 2Health News:Law Offices of D.R. Jones Client Wins 4.7 Million Dollar Verdict, Insurance Company Files Motion for a New Trial 3Health News:Gene Study Finds No Proof Vitamin D Guards Against Type 2 Diabetes 2
... Mii amo, a destination spa,at Enchantment Resort, for ... the winter solstice on December 21. Activities include ... Native,American Program Director R.J. Joseph and special guest, ... Elder from the Blood Reserve,in Standoff, Alberta, Canada,s ...
... planned bequest comes at stem cell symposium, ANN ... retail pioneer A. Alfred Taubman announced a $22 million ... research institute aimed at,understanding, treating and preventing human disease., ... it again --,announcing that he will bequeath an additional ...
... a Man Wanted to Know But Was Afraid to ... 4.3 million babies born,in the U.S. each year but ... BEING DAD is a revealing, entertaining and inspirational DVD ... who,have recently gone through the pregnancy and delivery process. ...
... developed a magnetic resonance imaging (MRI)-based method for detecting and ... in patients who have undergone a procedure to treat atrial ... Oct. 7, 2008, issue of the Journal of the ... is an arrhythmia, or abnormal heart rhythm, that involves the ...
... (OTCBB:WYND), the ideas-to-revenues social media company, announced ... www.muveinc.com ), to create an interactive marketing ... corporate wellness program. Wyndstorm,s design project will ... use of wellness programs among employees via ...
... 7 The Catholic Health,Association of the United ... (CHI), Denver; Covenant Health Systems, Lexington, MA;,and Trinity ... effort to,raise awareness about global climate change., ... National Religious,Partnership for the Environment (NRPE) and the ...
Cached Medicine News:Health News:Mii amo Honors Winter Solstice With Traditional Native American Celebration December 18-21 2Health News:Alfred Taubman Announces New $22M Gift to U-M 2Health News:BEING DAD DVD Offers a Sneak Peek at Pregnancy From a Guy's Point of View 2Health News:Novel imaging approach may assist in predicting success of treatment for atrial fibrillation 2Health News: 3D Social Media Application Aims to Cut Workplace Obesity : Muve, Inc., Selects Social Media Developer Wyndstorm Corporation to Design Online Promotions for Corporate Wellness Program 2Health News: 3D Social Media Application Aims to Cut Workplace Obesity : Muve, Inc., Selects Social Media Developer Wyndstorm Corporation to Design Online Promotions for Corporate Wellness Program 3Health News:Catholic Health Organizations Launch Ministry-Wide Effort to Raise Awareness About Global Climate Change 2
DNA/RNA preparation in 8-multi channels...
... units with hydrophobic PTFE membranes,Millex filter ... ideal for the sterilizing filtration of ... and for sterilizing or clarifying organic ... filter units are available with different ...
... Bottled Water, The Simplicity personal water system ... currently use bottled water. In addition to ... store bottled water, your laboratory applications may ... be absorbed from containers and cause water ...
... of Type I ultrapure water, , Ultrapure ... System is designed to provide the "final ... by reverse osmosis, distillation or deionization. Super-Q ... which exceeds Type I ASTM/CAP/NCCLS specifications.,The Super-Q ...
Medicine Products: